Shares of Agilent Technologies, Inc. (NYSE:A) bought by Bailard Inc.

Bailard Inc. increased its position in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) by 4.4% during the second quarter, Holdings Channel.com reports. The firm owned 2,613 shares of the medical research company’s stock after buying an additional 111 shares during the quarter. The holdings of Bailard Inc. in Agilent Technologies were worth $339,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in Agilent Technologies in the 1st quarter valued at approximately $938,000. Cetera Investment Advisers boosted its holdings in Agilent Technologies by 953.3% in the first quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock valued at $4,757,000 after purchasing an additional 29,590 shares in the last quarter. UBS Group AG raised its position in Agilent Technologies by 84.5% in the fourth quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock valued at $45,281,000 after buying an additional 149,159 shares during the period. TD Asset Management Inc raised its position in Agilent Technologies by 27.1% in the fourth quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock valued at $223,758,000 after buying an additional 343,175 shares during the period. Finally, iA Global Asset Management Inc. boosted its stake in Agilent Technologies by 26.2% in the first quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock worth $3,168,000 after purchasing an additional 4,523 shares during the last quarter. 87.42% of the shares are currently owned by institutional investors and hedge funds.

Agilent Technologies trading down 0.3%

Shares of Agilent Technologies stock opened at $140.50 on Tuesday. The company’s fifty day moving average is $134.34 and its two hundred day moving average is $138.65. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64, and a current ratio of 2.15. The company has a market cap of $40.99 billion, a P/E ratio of 33.22, a PEG ratio of 4.86 and a beta of 1.05.

Agilent Technologies (NYSE:A – Get Your Free Report ) last posted its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. In the same quarter last year, the firm posted EPS of $1.43. The company’s revenue for the quarter was down 5.6% year over year. Analysts estimate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Insider Trading at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the transaction, the chief executive officer now owns 25,185 shares in the company, valued at approximately $3,274,050. The sale was disclosed in a legal filing with the SEC, which can be accessed via this link. In related news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the sale, the senior vice president now directly owns 49,486 shares in the company, valued at $6,595,494.08. The transaction was disclosed in a filing with the SEC, which can be accessed via this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The disclosure for this sale can be found here. Insiders have sold 20,874 shares of company stock worth $2,811,770 over the last 90 days. 0.33% of shares are currently owned by insiders.

Analyst upgrades and downgrades

Several equities analysts have covered the company. Evercore ISI upped their target price on Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research report on Thursday, August 22nd. Citigroup upped their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. UBS Group upped their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday. Finally, Jefferies Financial Group reissued a “hold” rating and set a $135.00 price objective (down from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd . One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.80, according to MarketBeat.com.

Get the latest research report on Agilent technologies

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application-focused solutions to the life sciences, diagnostics and applied chemistry markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; systems and components for gas chromatography; mass spectrometry systems for gas chromatography; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; spectroscopy remain; cell assay plate assays; flow cytometer; real-time cell analyzer; cellular imaging systems; microplate reader; laboratory software; information management and analysis; laboratory automation and robotic systems; dissolution testing; and vacuum pumps and measurement technologies.

Read more

Want to see what other hedge funds own A? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Agilent Technologies, Inc. (NYSE:A – Free Report).

Get daily news and reviews for Agilent Technologies – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Agilent Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.